key: cord-1047051-jcnv9zxr
authors: Galozzi, Paola; Bindoli, Sara; Doria, Andrea; Sfriso, Paolo
title: Progress in Biological Therapies for Adult-Onset Still’s Disease
date: 2022-04-21
journal: Biologics
DOI: 10.2147/btt.s290329
sha: bd0f0bb299b4857523d76464376729c1ba638bd1
doc_id: 1047051
cord_uid: jcnv9zxr

Adult-onset Still’s disease (AOSD) is a rare multifactorial autoinflammatory disorder of unknown etiology, characterized by an excessive release of cytokines triggered by dysregulated inflammation and articular and systemic manifestations. The clinical spectrum of AOSD ranges from self-limiting forms with mild symptoms to life-threatening cases and presents clinical and biological similarities with the juvenile form (sJIA). Nowadays, the advances in biologic agents no longer limit the treatment to NSAIDs, glucocorticoids, or conventional synthetic DMARDs. The blockade of IL-1 and IL-6 is effective in the treatment of systemic and articular inflammation of AOSD patients; however, novel compounds with different properties and targets are now available and others are being studied. In this review, starting from the pathogenesis of AOSD, we summarized the current and emerging biological therapies, possible effective agents for achieving AOSD control and remission.

Non-Steroid Anti-Inflammatory Drugs (NSAIDs), Glucocorticoids, and Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) NSAIDs represent the first line therapy, especially when systemic manifestations are almost absent. 22 However, nearly 20% of the patients present a self-limited disease and for most of them NSAIDs fail in control of the disease activity. 23 Nevertheless, NSAIDs should be used as a supportive treatment during the diagnostic process. Indeed, high dose indomethacin (150-250 mg/day) or ibuprofen 800 mg up to 4-times a day may control some of the inflammatory manifestations satisfactorily. 1, 23 Of course, possible side-effects related to the prolonged employment of NSAIDs should be considered, such as gastrointestinal bleeding and for older patients the risk of renal or hepatic insufficiency. [24] [25] [26] Glucocorticoids represent an efficient choice in approximately 80% of the patients at the initial dose of 0.5-1 mg/kg/ day of methylprednisolone. 27 The response achievement is usually prompt and sustained on both articular and systemic manifestations. However, prolonged therapy with steroids should be avoided because of the risk of side-effects and adverse reactions including hypertension, diabetes, tachycardia, the possibility of early-onset osteoporosis, the occurrence of ecchymosis, and weight gain. 23 On the other hand, it should be considered that a quick reduction of steroid daily-intake may lead to disease relapses, thus the decrease of the posology should be done gradually. Sometimes, methylprednisolone can be insufficient in controlling the most severe manifestations, especially in those presenting with refractory forms or in patients who present with MAS features. In those cases, other types of glucocorticoids such as dexamethasone should be considered, in the same way as it is employed in the HLH-2004 protocol for the treatment of primary HLH. 28 However, a current defined posology for dexamethasone in severe AOSD has not been defined yet, Regarding csDMARDS, they are typically considered glucocorticoid-sparing drugs and are usually added to glucocorticoids or NSAIDs to obtain an adequate disease control. Nowadays, their use is quite limited since biological DMARDs are preferred as second line therapy. Methotrexate and Cyclosporine A were the most frequently employed, especially for the treatment of the chronic articular pattern and for MAS, respectively, while data with azathioprine or leflunomide come from small case series or case reports and are scarce. 1

It was reported in different observational studies that 17-32% of AOSD patients can be resistant to both first-line corticosteroids and second-line csDMARDs. 23, [29] [30] [31] Indeed, the systemic inflammation present in AOSD subjects depends on the increase of pivotal pro-inflammatory cytokines, such as IL-1, IL-6, IL-18, IL-17, and TNFα, which correlate with disease activity. 32 For this reason, nowadays, targeted biological treatments have emerged to be effective approaches for the management of AOSD, especially for the refractory form steroid-dependent or when severe manifestations occur. 23 However, there is no systematic criteria to select the correct drugs nor indications for biologics treatment suspension once clinical remission is achieved. In patients with systemic AOSD, response to IL-1 inhibitors must be expected within hours or days. It has been suggested that a cautious tapering of the drug could be attempted if clinical remission is maintained for at least 6-12 months. 33 

Anti IL-1 agents undoubtedly represent the milestone for the treatment of AOSD. To date, three IL-1 inhibitors are available for AOSD. IL-1 inhibitors have an overall satisfactory safety profile in AOSD. In terms of the risk of infection, treatment with anti-IL-1 agents seems to have an acceptable safety profile. Although the inhibition of IL-1 remains the gold standard in systemic AOSD and in the refractory forms, 34 other approaches should be considered.

Anakinra, a non-glycosylated form of human IL-1 receptor antagonist (IL-1Ra), acts as a pure receptor antagonist binding to the IL-1 receptor (IL-1RI) and preventing the activation of this receptor by either IL-1β or IL-1α. 35 Anakinra was firstly approved in 2001 for the treatment of rheumatoid arthritis, but the first employment in AOSD dates back to 2005 when the first cases were described. [36] [37] [38] As several studies report, it seems that anakinra is more effective if administered early in the disease course and it was proved to be more useful in patients with highly active systemic AOSD than in those with isolated chronic arthritis. 39 The confirmed effectiveness of anakinra was assessed in diverse observational studies by now. [40] [41] [42] [43] [44] Ortiz-Sanjuan et al 45 reported nearly 40 patients who experienced a marked reduction of the frequency of joint manifestations (from 87.8% at baseline to 41.5% after 12 months), of cutaneous rash (from 58.5% to 7.3%), fever (from 78% to 14.6%), lymphadenopathy (from 26.8% to 4.9%), and ferritin serum levels (from 63.4% to 36.6%) after 1year of therapy with anakinra. In addition, a general decrease of steroid daily intake was noticed (p<0.01). Similar results were achieved in a larger cohort of 136 consecutive AOSD patients that, after anakinra, exhibited a significant reduction of Pouchot's score from the baseline (p<0.0001) until the last follow-up period (12 months), with no major safety concerns. 46 Anakinra is usually administered at the dosage of 100 mg/day but given the short half-life (6-8 hours) in cases of insufficient response it can be increased to 200 mg, split into twice-daily administrations. 1 Treatment with anakinra has been associated with frequent injection-site reactions and occasionally severe cases of hepatotoxicity, reversible after treatment withdrawal. 44 efficacy and the safety of canakinumab in a subgroup of young adolescents with SJIA aged ≥16 years which were representative of an adult population. The phenotypic dichotomy of AOSD with the prevalence of systemic symptoms rather than polyarthritis reflects on the diverse possible therapeutical approaches. In this context, the CONSIDER trial (a multicenter, randomized, double-blind, placebo-controlled trial), which aimed to employ canakinumab in AOSD subjects with active joint involvement, did not achieve the primary endpoint (p=0.18) defined as the change in disease activity score (ΔDAS28>1.2). 48, 49 These results pave the way to new therapeutical strategies, which should be tailored on each patient according to the clinical phenotype presented.

Among other IL-1 inhibitors, it should be mentioned that Rilonacept (IL-1 trap molecule), a construct of two extracellular chains of the IL-1R complex (IL-1R plus IL1RAP), fused to the Fc portion of human immunoglobulin G1 (IgG1). Rilonacept can bind both IL-1β and IL-1α with high affinity and its half-life is longer than that of anakinra. 1 For this reason, it was successfully used at 160 mg/week in some refractory forms with a predominant articular involvement as a steroid-sparing agent. 50, 51 However, Rilonacept is currently FDA-approved only for the treatment of recurrent pericarditis.

IL-6 is a pro-inflammatory cytokine downstream of IL-1, and it represents a therapeutic target as well for AOSD.

Tocilizumab (TCZ) is a humanized anti-IL-6 receptor antibody that recognizes both membrane-bound and soluble forms of IL-6 receptor, specifically blocking IL-6. It is administered subcutaneously at doses of up to 8 mg/kg every 2 weeks. 52 The efficacy of TCZ was proved in cases of refractory AOSD, especially when the chronic articular pattern was predominant. 53, 54 However, the confirmation of its effectiveness on articular manifestation derived from a randomized clinical trial of 2018. 55 The same study also reported TCZ as acceptable in terms of safety.

Sarilumab (anti IL-6Rα) is a fully human anti-IL-6Rα mAb that binds membrane-bound and soluble human IL-6Rα with high affinity. 56 So far, the efficacy of sarilumab in AOSD was reported only in one patient who was successfully treated after developing resistance to TCZ. 57 The rationale of switching to sarilumab in TCZ-resistant subjects derives from the data obtained from the ASCERTAIN EXTEND trial (NCT01146652) on patients affected by rheumatoid arthritis. 58 The hypothesis of using sarilumab in refractory cases relies on the fact that in systemic AOSD the high levels of IL-6 may overwhelm the neutralizing capability of TCZ, therefore the direct inhibition of the IL-6 receptor might help to reduce more thoroughly the pro-inflammatory activity of IL-6. The same trial (NCT01146652) evaluated the safety of sarilumab, showing that the incidence rate of adverse events of special interest was generally stable, without any signal for increased rate over time.

Among TNF-α inhibitors, infliximab, etanercept, and adalimumab were the first biologicals used in single case reports or small series in the early 2000s. 59 The first employment of infliximab date to 2001, when it was administered i.v. at a dose of 3-5 mg/kg in three refractory Still's patients with success. 60 Other cases regarding the use of infliximab are reported in the literature. 61 Data with etanercept, the recombinant soluble form of the human 75-kDa TNF-receptor fusion protein, derive mostly from a small case series in which an improvement of the articular involvement has been observed after biweekly doses of 25 mg s.c in half of the patients with no occurrence of adverse reactions. 62 However, the convincing results with TNF-α inhibitors seen at the start were not confirmed by Fautrel et al, 63 who noticed a complete remission of symptoms only in five out of 20 patients treated with either infliximab or etanercept. Finally, data with adalimumab are mixed and scarce 64, 65 and, for this reason, in AOSD other biological approaches are nowadays preferred to anti-TNFalpha in terms of efficacy and safety. Indeed, a recent meta-analysis showed that the efficacy of TNFα inhibitors on clinical and laboratory manifestations is significantly lower than that of other biologic treatments and the observed adverse reactions, including serious infections, may lead to TNFα inhibitors discontinuation. 66 Other Therapeutical Approaches Rituximab, a chimeric anti CD-20 monoclonal antibody, is approved for rheumatoid arthritis, but the experience in AOSD (administered at 375 mg/m 2 given twice at 4-week intervals) is limited and for selected cases. 67, 68 Likewise, the employment of abatacept, a co-stimulation modulator that inhibits T-lymphocyte activation by binding to CD80 and CD86 and blocks the interaction with CD28, exhibited mixed and scarce results. 69, 70 Concerning intravenous immunoglobulin (IVIGs) they were proved to be effective and well-tolerated at the usual dose of 2 g/kg in 2-5 days every month in half of the patients in two open-label studies; 71,72 however, they should be employed in selected cases or when lifethreatening manifestations occur.

Alongside biologics that have now entered the therapeutic routine of AOSD patients, scientific efforts have produced new compounds with different pharmacokinetic and dynamic properties ( Table 1 ). Oral small molecules such as JAK or new anti-cytokine have been developed, so AOSD patients refractory to a specific biologic drug could be easily switched to an alternative highly effective treatment.

IL-18 is a pro-inflammatory cytokine belonging to the IL-1 superfamily, whose activity is tightly regulated by natural IL-18 binding protein (IL-18BP). As previously described, elevated levels of IL-18 during the active phase of AOSD give it the role of a potential biomarker. 14 Actually, three IL-18 inhibitors are under evaluation; however, data on the clinical efficacy of IL-18 blockade is still limited.

As recombinant human IL-18BP, tadekinig alfa binds IL-18 with a high affinity and in turn inhibits the secretion of TNFα, IFN-γ, and IL-1. 73 The most comprehensive study is a Phase II clinical trial showing early clinical and laboratory efficacy independent of dosage (80 mg or 160 mg 3-times per week s.c.) in 23 patients with long-standing multidrugresistant disease. 74 In fact, 50% of patients had previously been treated with csDMARD and with previous biologic agents in about one third of patients. The response rate was nearly 50% with an overall good safety profile. Similar to anakinra, the most frequent adverse event was injection site reaction; mild upper airway infections and arthralgia were also reported. A recent study evaluating the prolonged treatment with tadekining alfa reported a maintained clinical remission and dropped levels of free IL-18 in serum within 2 hours after injection. 75 

AVTX 007 (formerly CERC 007, AEVI 007, or MEDI 2338) is a high affinity, fully human anti-IL-18 monoclonal antibody, being developed for the treatment of autoinflammatory diseases, potentially including AOSD, sJIA, and multiple myeloma. Early stage clinical development is underway in the USA (NCT04752371). The Phase I multicenter, open-label study plans to include 12 patients, six of whom will be administered AVTX-007 intravenous (i.v.) at a dose of 7 mg/kg. Based on safety results in the first cohort, six other participants will be administered a dose escalation or reduction of AVTX-007. Safety, tolerability, and efficacy will be evaluated.

APB R3 is a long acting recombinant fusion protein composed of IL-18BP fused via a peptide linker to anti-human serum albumin Fab fragment (SAFA). SAFA is a platform technology to produce long-acting therapeutics by modifying antiserum albumin Fab avoiding lysosomal degradation and thereby prolonging the half life of the molecule. As at October 2021, early research of APB R3 is underway for the treatment of adult-onset Still's disease in South Korea. Anti IFN-γ IL-18 is a potent inducer of IFN-γ which has been found elevated in patients with macrophage activation syndrome complicating sJIA. 77 Recent reports 20,78 on the efficacy of an IFN-γ antibody (emapalumab) on cases of MAS 

complicating sJIA has grown great expectations on the potential efficacy of novel therapeutic agent. However, data regarding the effectiveness and safety of the IFN-γ blockade in treating AOSD remain limited.

Emapalumab is a fully human monoclonal antibody that neutralizes both free-and receptor-bound IFN-γ by inhibiting receptor dimerization and the signaling transduction. 79 The efficacy of emapalumab was recently assessed in a clinical trial enrolling 34 young patients with a diagnosis of primary HLH. 20 Although the 27 pretreated patients were reported to have worsened or reactivated disease, an unsatisfactory response, or adverse events, only 15% had fever, 70% thrombocytopenia, and 78% hyperferritinemia. However, the study by Locatelli et al 20 does not present convincing data for strong efficacy of emapalumab in patients with primary HLH. Recently, Gabr et al 80 reported that emapalumab effectively eliminated fever and improved laboratory outcomes of a patient with AOSD complicated by MAS.

Unlike the inhibition of targeted cytokines, Janus kinase (JAK) inhibitors can block a large variety of proinflammatory molecules through the competitive interaction with JAK region required for downstream JAK/STAT signaling. JAK inhibitors indeed prevent the effect of IL-6, IL-10, IFN-γ, IFN-α, and granulocyte-macrophage colony-stimulating factor (GM-CSF), which are strongly implicated in the AOSD pathogenesis. 81 Baricitinib and Ruxolitinib are more selective toward JAK1/2, while tofacitinib is more effective to JAK3. 82 Due to the modulating effect on the immune response, JAK inhibitors have a good chance of becoming a very promising treatment in heterogeneous disorders, such as AOSD. However, data regarding the effectiveness and safety of JAK inhibitors in treating AOSD remain limited to case reports.

Baricitinib, a JAK1/2 inhibitor, was reported by Kacar et al 83 as effective in treating two AOSD patients refractory to csDMARDs and other biologics. The combination with anakinra effectively treated a patient with refractory AOSD; 84 this observation is partially confirmed by Gillard et al 85 in another case. The authors also reported two cases with a concomitant use of baricitinib and steroids but there was no response to therapy at the last follow-up.

Tofacitinib, a JAK1/3 inhibitor, has recently been approved by the FDA for polyarticular JIA and is currently under evaluation (5 mg twice daily) in a double-blind trial for sJIA (NTC03000439). At present, only case reports support the use of tofacitinib in Still's disease complicated by MAS, 86 as well as the studies on animal models of HLH. 87 Besides, a recent report revealed the successful use of tofacitinib in 14 patients with AOSD. 88

The JAK1/2 inhibitor ruxolitinib is known to significantly reduce the proliferation and activation of immune modulating IFN-γ and other cytokines on experimental murine models of HLH. 89 Therefore, ruxolitinib may be considered for patients with secondary HLH. Indeed, a pilot study in 12 children with secondary HLH showed a good clinical response after 28 days of oral treatment. 90 Partial response was also reported for two Still's patients with the concurrent use of steroids. 85

An increase of IL-17 in AOSD has been reported 91 and is involved in the recruitment of neutrophils, thus contributing to the maintenance of the inflammatory phenotype. 92 Thus, the use of IL-17 inhibitors could be an effective and safe therapeutic option, especially in the chronic patients. However, more evidence and more treated cases are awaited.

Secukinumab is a human monoclonal antibody that binds to and neutralizes IL-17A. It is currently approved in many countries to treat psoriasis, ankylosing spondylitis, non-radiographic axial spondyloarthritis (SpA), and psoriatic arthritis with a favorable safety profile. Mitrovic et al 93 

Galozzi et al Dovepress suggest a phenotype shift rather than an overlap between the two diseases. Moreover, one has to keep in mind that the manifestations of SpA should be differentiated from the forms of Still's disease with chronic articular damage.

The use of anti IL-1 agents is already known to give a fast and robust response in the majority of AOSD cases. Furthermore, both articular and systemic manifestations can respond to this approach, that has shown efficacy in specific organ involvements as well as in other systemic complications of diseases such as hyperinflammation, cytokine storm, and MAS. 32 

Although anti-cytokine agents are characterized by a good safety profile that allows long periods of continued treatment, it would be reasonable to believe that the risks may outweigh the benefits once an inactive disease state is achieved. In these regards, new strategies for the treatment of the adult form of Still's disease are now under consideration.

Great attention was recently addressed to the blockade of the inflammasome NLRP3 and its components, that are wellknown to be involved in autoinflammatory processes. So far, different compounds able to bind NLRP3 and consequently the release of IL-1 have been investigated.

Dapansutrile (OLT1177), an orally active beta-sulfonyl nitrile, functions as a direct inhibitor of NLRP3 and it is currently tested in gout. 95 The first proof-of-concept, phase II trial on adult gouty patients was recently carried out in The Netherlands and dapansutrile was orally administered at variable dosages, eliciting a significant reduction of joint tenderness and swelling. 96 In addition, a dampening of pro-inflammatory cytokines, and in particular IL-6, was noticed. Despite the limitations of this preliminary study, the combination of its efficacy, the good safety profile, and the oral administration make dapansutrile a promising therapeutical option not only for gouty patients, but it is conceivable it could also be employed in AOSD, in particular in those patients having a predominant articular involvement.

By now, other blockers of NLRP3 or its components are under examination. MCC950 directly binds to the NACHT domain and inhibits the inflammasome assembly by hampering ASC oligomerization. 97 This compound was proven to reduce IL-1β production in vivo and in mouse models of CAPS. 98 A similar mechanism was described for CY09 which affects the NLRP3 ATPase activity hindering the assembly of NLRP3 itself. 99 On CAPS there are currently ongoing studies with Inzomelid (NCT04015076), another oral selective NLRP3 inhibitors, and tranilast (NCT03923140), an anthranilic acid able to bind the NACHT domain; 99 diacerein, an anthraquinone compound, may downregulate both NLRP3/caspase-1/IL-1β either the IL-6/pSTAT3 axis, 100 while belnacasan (VX-765) and A1-AT target directly the caspase I component blocking the IL-1β release. 95, 101 Despite the studies on these inflammasome inhibitors currently being at an early stage, it is conceivable they could have future employment in Still's disease.

Another target that has been investigated in recent times is GM-CSF. 102 GM-CSF can upregulate neutrophils and macrophages, can induce the formation of NETs, and in turn enhances the production of pro-inflammatory cytokines by binding to its receptor. 

In this context, mavrilimumab (CAM-3001), an IgG4 monoclonal antibody (mAB), and otilimab (MOR-103), an IgG1 mAB, can bind the GM-CSF-alpha receptor and GM-CSF, respectively, preventing the release of pro-inflammatory cytokines. Both otilimab and mavrilimumab were proved to be effective and safe in rheumatoid arthritis patients, providing a significant reduction of DAS28-CRP in the clinical trials carried out by now. [103] [104] [105] In addition, mavrilimumab was recently employed for the treatment of severe COVID-19 pneumonia, relying on the fact that the inhibition of GM-CSF could curb the hyperinflammation provoked by the virus. 106 For this reason, it is conceivable these inhibitors could be used for treating both the chronic articular pattern and the systemic form of Still's disease.

Recently, the expression signature of long non-coding RNAs (lncRNAs) in AOSD patients was investigated to understand whether they could correlate with the disease phenotype. LncRNAs are known to be central regulators of the immune responses [107] [108] [109] [110] and their expression is associated to certain pathways or cytokines that contribute to AOSD pathogenesis. For example, NEAT-1 (nuclear enriched abundant transcript 1) levels, detected in serum samples of AOSD patients, strongly correlate with the expression of other lncRNAs after cyclosporine or anti IL-6, while they were not observed before starting the treatments. NEAT-1 can upregulate the PI3K/Akt/mTOR and TRAF6-NfkB axis and in turn regulates the production of IL-6, IL-17, and TNF-α. Similarly, MIAT (myocardial infarction associated transcript) was described as a suppressor on TNF-α and IL-1β, while, on the other hand, THRIL (TNF-alpha and hnRNPL-related immunoregulatory lincRNA) was found to upregulate TNF-α; in AOSD indeed, high levels of MIAT and a low expression of THRIL were observed in comparison to healthy controls. 111 Taken together these results suggest that, according to the different type of lncRNA signature detected, it is possible to understand the axis, or the group of cytokines mostly involved in AOSD pathogenesis and, thus, managing properly the patients contributing to the treat-to target strategy.

Recent advances in biologic drug development have had a major impact on AOSD patients in terms of improved qualityof-life and coping strategies. Specific inhibition of IL-1 and IL-6 is now considered a safe and effective therapy to better control the disease. As reported in this work, there are currently a number of biological agents, possible effective targets for achieving AOSD control and remission. The early and targeted blockade of the inflammation is critical for treatment, and early biological therapies in an appropriate window-of-opportunity is expected in the near future.

Adult-onset still's disease: molecular pathophysiology and therapeutic advances

Adult onset Still's disease in the elderly: a case-based literature review

Adult-onset Still's disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies

Preliminary criteria for classification of adult Still's disease

Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease

Validation of the Fautrel classification criteria for adult-onset Still's disease

Adult onset Still's disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions

Cytokine profile in adult-onset Still's disease: comparison with systemic juvenile idiopathic arthritis

New markers for adult-onset Still's disease

Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity

Adult-onset Still disease

Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still's disease

Roles of interactions between toll-like receptors and their endogenous ligands in the pathogenesis of systemic juvenile idiopathic arthritis and adult-onset still's disease

Cytokine storm in COVID-19: the current evidence and treatment strategies

Cytokine storm in coronavirus disease 2019 and adult-onset still's disease: similarities and differences

First manifestation of adult-onset Still's disease after COVID-19

Macrophage activation syndrome associated with adult-onset Still's disease: a multicenter retrospective analysis

Predictive factors and prognosis of macrophage activation syndrome associated with adult-onset Still's disease

Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature

Emapalumab in children with primary hemophagocytic lymphohistiocytosis

Complications of adult-onset Still's disease and their management

Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease

Current treatment options and safety considerations when treating adult-onset Still's disease

Hepatocellular damage from non-steroidal anti-inflammatory drugs

Variation in the risk of peptic ulcer complications with nonsteroidal antiinflammatory drug therapy

Renal syndromes associated with nonsteroidal antiinflammatory drugs

Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients

Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation

Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: data from a large multicenter cohort

Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients

Clinical features and prognosis of adult-onset Still's disease: 75 cases from China

Mechanisms, biomarkers and targets for adult-onset Still's disease

How I treat patients with adult onset Still's disease in clinical practice

Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: countrywide data in 50 patients

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

Successful treatment of a patient with refractory Adult-onset Still disease with anakinra

Rapid responses to anakinra in patients with refractory adult-onset Still's disease

Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature

Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra: a case report

Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a caseseries study

Anakinra in adult-onset still's disease: long-term treatment in patients resistant to conventional therapy

Interleukin 1 inhibition with anakinra in adult-onset still disease: a meta-analysis of its efficacy and safety

Efficacy of anakinra in refractory adult-onset still's disease multicenter study of 41 patients and literature review

Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset still's disease: a multicentre retrospective observational study

Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups

Canakinumab for treatment of adult-onset still's disease to achieve reduction of arthritic manifestation (CONSIDER): Phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial

Efficacy and safety of canakinumab in the treatment of adult-onset Still's disease: a systematic review

Safety and efficacy of IL-1 Trap in resistant adult onset Still's disease: 24 month follow-up of open label treatment and biomarkers of response

IL-1 Trap rilonacept in refractory adult onset Still's disease

Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients

Tocilizumab for the treatment of adult-onset Still's disease: results from a case series

Tocilizumab in refractory adult still's disease

Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled Phase III trial

Sarilumab: a review in moderate to severe rheumatoid arthritis

Efficacy of sarilumab in adult-onset Still's disease as a corticosteroid-sparing agent

Efficacy of sarilumab in patients with rheumatoid arthritis who previously received sarilumab or tocilizumab

Biologic treatments for adult-onset Still's disease

Infliximab in the treatment of adult Still's disease refractory to conventional therapy

Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences

Etanercept in the treatment of adult patients with Still's disease

Tumour necrosis factor α blocking agents in refractory adult Still's disease: an observational study of 20 cases

Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still's disease: the first case report

Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade

Biological therapy of traditional therapy-resistant adult-onset Still's disease: an evidence-based review

Successful treatment of refractory adult onset Still's disease with rituximab

Successful treatment of refractory adult-onset Still's disease with anti-CD20 monoclonal antibody

Efficacy of Abatacept in a refractory case of adult-onset Still's disease

Refractory adult-onset still disease successfully treated with Abatacept

Treatment of Still's disease in adults with intravenous immunoglobulins

Intravenous immunoglobulin in adult Still's disease refractory to non-steroidal anti-inflammatory drugs

Interleukin-18 and IL-18 binding protein

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease

Prolonged treatment with Tadekinig alfa in adult-onset Still's disease

Adisinsight Drug Profile: APB R3

Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

Emapalumab, an interferon gamma (IFN-Y)-blocking monoclonal antibody, in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (SJIA)

Investigating the novel mechanism of action for NI-0501, a human interferon gamma monoclonal antibody

Successful treatment of secondary macrophage activation syndrome with emapalumab in a patient with newly diagnosed adult-onset Still's disease: case report and review of the literature

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases

Mixed results with baricitinib in biological-resistant adult-onset Still's disease and undifferentiated systemic autoinflammatory disease

Treatment of refractory adult onset Still's disease with combination anakinra and baricitinib therapy

AB0772 Jak inhibitors in refractory adult and childhood onset still's disease

Tofacitinib-induced remission in refractory adult-onset Still's disease complicated by macrophage activation syndrome

Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice

Tofacitinib in refractory adult-onset Still's disease: 14 cases from a single centre in China

Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis

A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis

Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart

Innate IL-17-producing cells: the sentinels of the immune system

Adult-onset Still's disease or systemic-onset juvenile idiopathic arthritis and spondyloarthritis: overlapping syndrome or phenotype shift? Rheumatology;2021. keab726

Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia

Autoinflammatory mechanisms in crystal-induced arthritis

Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an openlabel, dose-adaptive, proof-of-concept, phase 2a trial

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases

MCC950/CRID3 potently targets the NACHT domain of wildtype NLRP3 but not disease-associated mutants for inflammasome inhibition

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders

Diacerein downregulates NLRP3/Caspase-1/IL-1β and IL-6/STAT3 pathways of inflammation and apoptosis in a rat model of cadmium testicular toxicity

Inflammasome inhibitors: promising therapeutic approaches against cancer

Current and emerging biological therapy in adult-onset Still's disease

MOR103, a human monoclonal antibody to granulocyte -Macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial

Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor α monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis

A randomized Phase IIb study of mavrilimumab and golimumab in rheumatoid arthritis

GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study

A long noncoding RNA mediates both activation and repression of immune response genes

Long non-coding RNAs (lncRNAs) and their transcriptional control of inflammatory responses

Long non-coding RNAs and control of gene expression in the immune system

Long non-coding RNAs and the innate immune response

Expression signature of inflammation-associated long non-coding RNAs in adult-onset Still's disease

EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use

The authors report no conflicts of interest in this work.